 Idarubicin second-generation anthracycline vitro activity leukemic cell lines Phase studies acute leukemia Phase II III clinical trials idarubicin hydrochloride patients acute lymphocytic leukemia acute nonlymphocytic leukemia Phase III comparative trials combinations idarubicin cytarabine daunorubicin hydrochloride cytarabine idarubicin/cytarabine combination complete remission rates overall survival studies US result Food Drug Administration intravenous idarubicin Class rating September use combination antileukemic drugs cytarabine treatment acute myelogenous leukemia adults recommended dose idarubicin days slow intravenous injection combination cytarabine idarubicin causes myelosuppression similar daunorubicin incidence cardiotoxicity animal models Idarubicin advantage oral administration oral formulation drug investigational use idarubicin pediatric patients